Publications by authors named "Prakash Bhuyan"

Claim this Profile
H
HPLC-MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum.
Alexander Schäfer, Peter Sagelsdorff, Björn Hock, Prakash Bhuyan, Norman Moullan

Anal Bioanal Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies.
Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Prakash Bhuyan

Infect Dis Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cervical High-Grade Squamous Intraepithelial Lesion Burden and Standard of Care Treatment Effectiveness and Safety in the United States, 2008-2018: The EACH-WOMAN Project.
Katherine C Hughes, Timothy A Herring, Jennifer N Song, Robert V Gately, Lindsey M Przybyl, Prakash K Bhuyan

J Low Genit Tract Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations.
Michael A Laffan, Sue Rees, Madhavi Yadavalli, Lisa Beth Ferstenberg, Nirmal Kumar Shankar, Prakash Bhuyan

Vaccine· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months.
Magdalena E Sobieszczyk, Jill Maaske, Ann R Falsey, Stephanie Sproule, Merlin L Robb, Prakash Bhuyan

J Clin Invest· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination.
Taylor S Cohen, Elizabeth J Kelly, Sven Nylander, Himanshu Bansal, Brett M Jepson, Prakash Bhuyan

Sci Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination.
Karina Soboleva, Nirmal Kumar Shankar, Madhavi Yadavalli, Cátia Ferreira, Nadia Foskett, Prakash Bhuyan

Lancet Glob Health· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
Prakash Bhuyan, Jennie Medin, Hugo Gomes da Silva, Madhavi Yadavalli, Magnus Nord

Lancet· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.
Prakash Bhuyan, Jennie Medin, Hugo Gomes da Silva, Madhavi Yadavalli, Nirmal Kumar Shankar

Lancet· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
Prakash K Bhuyan, Michael Dallas, Kim Kraynyak, Timothy Herring, Matthew Morrow

Hum Vaccin Immunother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population.
Rebecca K Hollenberg, Diane R Krieger, Robert Samuels, Kim Kraynyak, Albert Sylvester, Prakash K Bhuyan

Hum Vaccin Immunother· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Derek Muse, Shane Christensen, Prakash Bhuyan, Judith Absalon, Joseph J Eiden

Pediatr Infect Dis J· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
Shelly Senders, Prakash Bhuyan, Qin Jiang, Judith Absalon, Joseph J Eiden

Pediatr Infect Dis J· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing historical control clinical trial data to provide safety context.
Prakash Bhuyan, Jigar Desai, Matthew St Louis, Martin Carlsson, Edward Bowen

Drug Discov Today· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.
David M Reiner, Prakash Bhuyan, Joseph J Eiden, John Ginis, Shannon Harris

Vaccine· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
Christopher L Gilbert, Jon E Stek, Giuseppe Villa, Stephanie O Klopfer, Jason C Martin, Prakash K Bhuyan

Vaccine· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
Scott A Halperin, Bruce Tapiéro, Marc Dionne, William Meekison, Francisco Diaz-Mitoma, Prakash Bhuyan

Pediatr Infect Dis J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
Bruce Tapiéro, Scott A Halperin, Mark Dionne, William Meekison, Francisco Diaz-Mitoma, Prakash Bhuyan

Pediatr Infect Dis J· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.
Gianmaria Minervini, Barbara J McCarson, Keith S Reisinger, Jason C Martin, Jon E Stek, Prakash K Bhuyan

Vaccine· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Christopher L Gilbert, Stephanie O Klopfer, Jason C Martin, Florian P Schödel, Prakash K Bhuyan

Hum Vaccin· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
Andrew W Lee, Timo Vesikari, Christopher L Gilbert, Stephanie O Klopfer, Florian P Schödel, Prakash K Bhuyan

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
Timo Vesikari, Jason C Martin, Charles L Liss, Vladimir Liska, Florian P Schödel, Prakash K Bhuyan

Pediatr Infect Dis J· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
Francisco Diaz-Mitoma, Scott A Halperin, Bruce Tapiero, Agnes Hoffenbach, Pamela S Zappacosta, Prakash K Bhuyan

Vaccine· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series.
Javier Diez-Domingo, Sheryl A Flores, Jason C Martin, Stephanie O Klopfer, Florian P Schödel, Prakash K Bhuyan

Pediatr Infect Dis J· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
Scott A Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, Barbara J Law, Agnes Hoffenbach, Prakash K Bhuyan

Vaccine· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis